Khoren Hekimian, DO
Family Medicine · Troup, TXNPI 1588695423
Payments from drug & device makers
Across 394 payments — averaging $31.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viatris Specialty LLC$5K
- Neurocrine Biosciences, Inc.$1K
- Mylan Specialty L.p.$865
- Avanir Pharmaceuticals, Inc.$764
- Sunovion Pharmaceuticals Inc.$678
- Teva Pharmaceuticals USA, Inc.$557
- plus $3K from 28 others
What the payments were for
- Consulting fees$3,73830%
- Travel & lodging$4934%
- Food & beverage$8,07465%
- Education$1281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viatris Specialty LLC | 15 | $4,771 |
| Neurocrine Biosciences, Inc. | 59 | $1,410 |
| Mylan Specialty L.p. | 32 | $865 |
| Avanir Pharmaceuticals, Inc. | 60 | $764 |
| Sunovion Pharmaceuticals Inc. | 50 | $678 |
| Teva Pharmaceuticals USA, Inc. | 28 | $557 |
| Acadia Pharmaceuticals Inc | 26 | $556 |
| Alpha Cognition USA, Inc. | 4 | $528 |
| UCB, Inc. | 12 | $285 |
| AstraZeneca | 10 | $275 |
| Lundbeck LLC | 15 | $226 |
| Astellas Pharma US Inc | 12 | $159 |
| Sumitomo Pharma America, Inc. | 9 | $153 |
| Lilly USA, LLC | 9 | $147 |
| Otsuka America Pharmaceutical, Inc. | 6 | $143 |
| Urovant Sciences Inc | 6 | $124 |
| Johnson & Johnson | 6 | $118 |
| Kyowa Kirin, Inc. | 5 | $114 |
| Alkermes, Inc. | 5 | $100 |
| Novartis | 5 | $92 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| Biogen | 3 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $45 |
| Indivior Inc. | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $22 |
| Vivus LLC | 1 | $21 |
| Almatica Pharma LLC | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,433 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 421 | $1,798,939 |
| EliquisApixaban | 2,883 | $836,039 |
| GemtesaVibegron | 1,136 | $276,132 |
| JardianceEmpagliflozin | 815 | $256,057 |
| TrulicityDulaglutide | 261 | $232,929 |
| NuplazidPimavanserin Tartrate | 83 | $223,666 |
| XareltoRivaroxaban | 734 | $208,786 |
| YupelriRevefenacin | 106 | $151,607 |
| TradjentaLinagliptin | 554 | $145,885 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 525 | $124,158 |
| JanuviaSitagliptin Phosphate | 408 | $115,834 |
| OzempicSemaglutide | 110 | $112,821 |
| Invega SustennaPaliperidone Palmitate | 42 | $111,577 |
| RybelsusSemaglutide | 193 | $106,484 |
| NuedextaDextromethorphan Hbr/Quinidine | 137 | $102,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,410 | $1,798,939421 claims |
| Johnson & JohnsonXarelto, Invega Sustenna, Prezcobix | $118 | $359,980793 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $153 | $276,1321,136 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $147 | $270,636299 claims |
| Acadia Pharmaceuticals IncNuplazid | $556 | $223,66683 claims |
| Mylan Specialty L.p.Yupelri | $865 | $151,607106 claims |
| Astellas Pharma US IncMyrbetriq, Cresemba | $159 | $135,643414 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $764 | $102,631137 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $557 | $98,53924 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $143 | $55,89784 claims |
| NovartisEntresto | $92 | $55,719156 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $42,4073,542 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Troup
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.